Amid Second Quarter Financial Results, Atreca Halts Development of Lead Drug
Company to focus on improving earlier stage antibody-drug conjugate candidates
Atreca, a clinical-stage biotechnology company, has announced its second quarter financial results. In order to reduce expenses, the organization revealed a plan to reduce expenses and implement cost-saving measures. As a part of the reorganization, Atreca will be reducing its workforce by an estimated 40 percent and suspending development of lead drug candidate ATRC-101. According to a company press release, operations will now focus on advancing current preclinical antibody-drug conjugate (ADC) candidates while preserving core discovery capabilities.
“In order to extend our cash runway and focus on our preclinical ADC development efforts, we are suspending development of ATRC-101,” said John Orwin, CEO, Atreca, in the previously mentioned release. “We are proud of our work in advancing ATRC-101 into the clinic and are encouraged by the activity and safety profile that we observed, validating the ability of our discovery platform to generate novel, tumor-targeting product candidates. Nevertheless, given both development requirements and financial considerations, we believe that the best path forward for the asset is with a larger partner, and as a result, we are suspending development and evaluating potential out-licensing opportunities. Our preclinical ADC pipeline, led by APN-497444, will continue to advance, and we are working towards declaring a clinical candidate from this program in the coming months.”
Reference: Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring. Atreca. August 10, 2023. Accessed August 11, 2023. https://ir.atreca.com/news-releases/news-release-details/atreca-reports-second-quarter-2023-financial-results-and
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
